Updated July 2026 investor presentation from Ernexa Therapeutics (NASDAQ: ERNA)

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. furnished an updated investor presentation as part of a current report on Form 8-K. The July 2026 presentation, attached as Exhibit 99.1, updates materials first posted in February 2026 and will also be available on the company’s investor relations website.

The company states that it routinely uses its website to distribute important information, including press releases, investor presentations and financial data, and offers email alerts when new materials are posted. The information in this item and Exhibit 99.1 is being provided as “furnished,” not “filed,” under the Exchange Act.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Terms

Forward-Looking Statements, Investor Presentation, furnished and not filed, Section 18 of the Securities Exchange Act of 1934, +1 more

5 terms

Forward-Looking Statements financial

"the “Forward-Looking Statements” disclosure contained in the Investor Presentation is incorporated"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Investor Presentation financial

"A copy of this updated presentation is attached hereto as Exhibit 99.1"

An investor presentation is a carefully prepared talk or visual display that explains a company's business, goals, and financial performance. It helps investors understand how the company operates and its future prospects, much like a report card or progress update. These presentations are important because they provide transparency and help investors decide whether to support or invest in the company.

furnished and not filed regulatory

"The information contained in this Item 7.01, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed”"

Section 18 of the Securities Exchange Act of 1934 regulatory

"for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended"

incorporated by reference regulatory

"shall not be incorporated by reference in another filing under the Exchange Act"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/02/2026 - 04:42 PM Accepted by SEC EDGAR 07/02/2026 - 04:40 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 2, 2026

Ernexa Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-11460

31-1103425

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1035 Cambridge Street, Suite 18A
Cambridge, MA		02141
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 798-6700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock, par value $0.005 per share	ERNA	The Nasdaq Stock Market LLC
Common Stock Purchase Warrants	ERNAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On July 2, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), made available an updated presentation for investors. This presentation updates the presentation posted on February 26, 2026. A copy of this updated presentation is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. A copy of the presentation will also be available on our website at https://investor.ernexatx.com on July 3, 2026.

Without limiting the generality of the foregoing, the “Forward-Looking Statements” disclosure contained in the Investor Presentation is incorporated by reference into this Item 7.01.

Use of our Website to Distribute Material Company Information

We use our website as a channel of distribution for important Company information. We routinely post on our website important information, including press releases, investor presentations and financial information, which may be accessed by clicking on either the “News” or “Investor Relations” sections of www.ernexatx.com. We may also use our website to expedite public access to time-critical information regarding our Company in advance of or in lieu of distributing a press release or a filing with the Securities and Exchange Commission (the “SEC”) disclosing the same information. Therefore, investors should look to the “News” or “Investor Relations” sections of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when certain new information is made available on our website. Information contained on, or accessible through, our website is not a part of and is not incorporated by reference in this Current Report on Form 8-K or in any of our other filings with the SEC.

The information contained in this Item 7.01, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Ernexa Therapeutics Investor Presentation – July 2026.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Ernexa Therapeutics Inc.

Dated: July 2, 2026	By:	/s/ Sanjeev Luther
		Sanjeev Luther
		President and Chief Executive Officer

-3-

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Ernexa Therapeutics (ERNA) disclose in this Form 8-K?

Ernexa Therapeutics furnished an updated investor presentation for July 2026. The presentation, attached as Exhibit 99.1, refreshes materials originally posted in February 2026 and is intended to provide investors with current company information and forward-looking statements.

When and where is Ernexa Therapeutics’ July 2026 investor presentation available?

The updated investor presentation was made available on July 2, 2026. A copy is attached as Exhibit 99.1 and is also accessible on Ernexa’s website, in the News or Investor Relations sections at https://investor.ernexatx.com starting July 3, 2026.

Is Ernexa Therapeutics’ investor presentation considered furnished or filed with the SEC?

The company specifies the investor presentation is “furnished” rather than “filed” under the Exchange Act. This means it is not subject to Section 18 liability and will only be incorporated into other filings if those filings explicitly incorporate it by reference.

How does Ernexa Therapeutics use its website for investor communications?

Ernexa uses its website as a channel to distribute important company information. It routinely posts press releases, investor presentations and financial information and may use the site to provide time-critical updates before or instead of separate press releases or additional SEC filings.

What exhibit numbers are included in this Ernexa Therapeutics Form 8-K?

The filing includes Exhibit 99.1, the Ernexa Therapeutics Investor Presentation – July 2026. It also lists Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document, which supports the electronic filing format requirements.

Filing Exhibits & Attachments

29 documents